NASDAQ:TCON

TRACON Pharmaceuticals Stock Forecast, Price & News

$6.56
+0.18 (+2.82 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.43
$6.69
50-Day Range
$5.66
$8.19
52-Week Range
$1.55
$12.20
Volume82,896 shs
Average Volume328,410 shs
Market Capitalization$101.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
30 days | 90 days | 365 days | Advanced Chart
Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

686th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

95th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

Is TRACON Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than TRACON Pharmaceuticals?

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for TRACON Pharmaceuticals
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02.
View TRACON Pharmaceuticals' earnings history
.

How has TRACON Pharmaceuticals' stock been impacted by COVID-19?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TCON shares have increased by 365.2% and is now trading at $6.56.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TCON?

5 brokerages have issued 1 year target prices for TRACON Pharmaceuticals' stock. Their forecasts range from $12.00 to $24.00. On average, they anticipate TRACON Pharmaceuticals' share price to reach $15.75 in the next year. This suggests a possible upside of 140.1% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:
  • Dr. Charles P. Theuer, CEO, Pres & Director (Age 57, Pay $905.38k)
  • Mr. Scott B. Brown CPA, M.S., Chief Financial Officer (Age 40, Pay $382.82k)
  • Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 65, Pay $543.99k)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 44)
  • Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo, Chief Medical Officer (Age 66)

Who are some of TRACON Pharmaceuticals' key competitors?

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.55%), Geode Capital Management LLC (0.68%), Ameriprise Financial Inc. (0.57%), Bank of New York Mellon Corp (0.55%), Millennium Management LLC (0.33%) and QS Investors LLC (0.28%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends for TRACON Pharmaceuticals
.

Which institutional investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, GSA Capital Partners LLP, Ameriprise Financial Inc., and We Are One Seven LLC.
View insider buying and selling activity for TRACON Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying TRACON Pharmaceuticals stock?

TCON stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, QS Investors LLC, Geode Capital Management LLC, Acadian Asset Management LLC, Bank of New York Mellon Corp, X Square Capital LLC, Dowling & Yahnke LLC, and Price T Rowe Associates Inc. MD. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier, and Scott B Brown.
View insider buying and selling activity for TRACON Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $6.56.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals has a market capitalization of $101.69 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-16,770,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does TRACON Pharmaceuticals have?

TRACON Pharmaceuticals employs 18 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

Where are TRACON Pharmaceuticals' headquarters?

TRACON Pharmaceuticals is headquartered at 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.